‹
›
This content requires a premium subscription.
Please
log in
or
subscribe
to continue.
<iframe title="Libsyn Player" style="border: none" src="//html5-player.libsyn.com/embed/episode/id/5989176/height/506/theme/custom/thumbnail/yes/direction/backward/render-playlist/no/custom-color/d4bf69/" height="506" width="100%" scrolling="no" allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen></iframe>
The Beacon
Should Osimertinib Become First-Line Treatment of Choice for EGFR Mutation-Positive Advanced NSCLC, or Should it Be Saved for Later? (BMIC-017)
30
00:00:00
/ 00:11:47
30
